Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Trial of Nabilone for the Treatment of Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Obese adults (BMI \> 30.0 kg/m2).~* For the optional imaging component of the study, a maximum weight (315 lbs) and a maximum girth in line with capacity of the machine (60 cm horizontal and 45 cm vertical; therefore, circumference of scanner is 166.6 cm)~* For women of reproductive potential (WORP) and men whose sexual partners are WORP: use of adequate methods of contraception (effective barrier methods such as male condoms, female condoms, cervical caps, diaphragms, or contraceptive sponges; and highly effective methods of contraception such as oral hormonal contraceptives, intrauterine devices (IUDs), vasectomy, or tubal ligation)~* AST/ALT, bilirubin, and kidney function tests within normal limits at screening.~Exclusion Criteria:~* Unstable gastrointestinal, respiratory, endocrinological, cardiovascular or cerebrovascular diseases that would prevent participation in the trial at QI (or its delegate) discretion,~* Unstable major psychiatric disorder(s) (i.e. Axis I Disorders) that would prevent participation in the trial at QI (or its delegate) discretion,~* Current substance use disorders (DSM-V) (excluding tobacco and caffeine),~* History of, or current neurological illnesses, that would prevent participation in the trial,~* Current use or use during the previous month of antipsychotic medications,~* Learning disability, amnesia or other conditions that impede memory and attention,~* Visual impairments that prevent participation in the study,~* Personal or family history of schizophrenia, or psychosis (or psychosis-related) disorders,~* Antibiotic use in the last 4 weeks,~* Previous bariatric surgery,~* Current use or use in the past month of other weight-loss pharmaceuticals,~* Cannabis use in last 6 months,~* Known sensitivity to cannabis or other cannabinoid agents,~* Pregnancy or lactation (females), and~* For the optional imaging component of the study:~  * Presence of metal implants or objects unsafe for MRI such as cardiac pacemakers, metal fragments in the eye, and aneurysm clips in your brain~ * Piercings or jewelry that are unable to be removed~ * Tattoos inked with metal dyes

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Low-Dose Nabilone (Type: EXPERIMENTAL): pms-nabilone titrated to 2 mg daily
- High-Dose Nabilone (Type: EXPERIMENTAL): pms-nabilone titrated to 6 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).